FDA grants Priority Review for IMAAVY® as the potential first approved treatment for people living with warm autoimmune hemolytic anemia
IMAAVY® shows over two years of sustained disease control in a broad population with generalized myasthenia gravis
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
ICOTYDE one-year results confirm lasting skin clearance and favorable safety profile in once?daily pill for plaque psoriasis
FDA approval of ICOTYDE ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson highlights promising first-in-human Erda-iDRS results in intermediate-risk non-muscle-invasive bladder cancer
